This a a very compelling set of research results. It proves with...

This a a very compelling set of research results.
It proves with very detailed clinical data that the screening and monitoring with L-DEX leads to statistically significant reduction in the development of Lymphodema.

It also states that L-DEX can pick up the early signs of Lymphodema that other measuring devices cannot. if that is not a clear indication of the results we are going to see in the 1,100 patient clinical trial, I am not sure what is.
The Oncologists are going to need to start performing these regular tests and make L-DEX the duty of care going forward. This will help the message get through and get private payers onboard.

This share has been unfairly beaten up due to lack of news flow and a very aggressive shorter!! Lets see if this changes the tide?